David R. Stover

6.3k citations

47 papers · 3.0k indexed · 1 hit paper · h-index 23

Impact in

Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
Gastroenterology top 2%
- Gastrointestinal Tumor Research and Treatment

Papers in

Hematology 9
- Multiple Myeloma Research and Treatments 5
Oncology 19
- Peptidase Inhibition and Analysis 8
- HER2/EGFR in Cancer Research 6

Co-authors: Nicholas Lydon Sayuri Ohno-Jones Catherine L. Cioffi Elisabeth Buchdunger Norman M. Law Brian Druker Janis Liebetanz Kenneth A. Walsh
Journals: Cancer Research (9 papers)Journal of Biological Chemistry (4 papers)Molecular Cancer Therapeutics (3 papers)European Journal of Biochemistry (2 papers)European Journal Of Haematology (2 papers)
Partner nations: United States Switzerland Germany

In The Last Decade

David R. Stover

46 papers receiving 3.0k citations

Hit Papers

align trajectories log scale

Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors 2000 · 1.0k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2000 Journal of Pharmacology and Experimental Therapeutics

Peers

Countries citing papers authored by David R. Stover

Since Specialization

Citations

This map shows the geographic impact of David R. Stover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Stover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Stover more than expected).

Fields of papers citing papers by David R. Stover

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Stover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Stover. The network helps show where David R. Stover may publish in the future.

Co-authors

The 25 scholars most cited alongside David R. Stover, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David R. Stover Line = papers co-authored together David R. Stover links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise Molecular Cancer Therapeutics ·Hui Zhao, Sara Gulesserian, Maria Christina Malinao, Sathish Kumar Ganesan, James Song, Mi Sook Chang, Melissa M. Williams, Zhilan Zeng, Michael Mattie, Brian A. Mendelsohn, David R. Stover, Fernando Doñate	2017	63
2	Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia Molecular Cancer Therapeutics ·Hui Zhao, Sara Gulesserian, Sathish Kumar Ganesan, Jimmy Ou, Karen Morrison, Zhilan Zeng, Verónica Robles, Josh Snyder, Lisa Do, Héctor Aviña, Sher Karki, David R. Stover, Fernando Doñate	2017	47
3	Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6 , a New Urothelial Cancer Biomarker Molecular Cancer Therapeutics ·Kendall Morrison, Pia M. Challita-Eid, Arthur Raitano, Zili An, Peng Yang, Joseph D. Abad, Wendy Liu, Dawn Ratay Lortie, Josh Snyder, Linnette Capo, Alla Verlinsky, Héctor Aviña, Fernando Doñate, Ingrid B.J. Joseph, Daniel S. Pereira, Karen Morrison, David R. Stover	2016	55
4	Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys Molecular Imaging and Biology ·Dean O. Campbell, Akihiro Noda, Alla Verlinsky, Josh Snyder, Yuji Fujita, Yoshihiro Murakami, Hiroshi Fushiki, Sosuke Miyoshi, Sergio Lacayo, Edward Cabral, Peng Yang, David R. Stover, Ingrid B.J. Joseph	2016	25
5	Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates Pharmaceutical Research ·Dowdy Jackson, David R. Stover	2014	28
6	Discoidin Domain Receptor 1 Contributes to Tumorigenesis through Modulation of TGFBI Expression PLoS ONE ·Nandini Rudra-Ganguly, Christine Lowe, Michael Mattie, Mi Sook Chang, Daulet Satpayev, Alla Verlinsky, Zili An, Liping Hu, Peng Yang, Pia M. Challita-Eid, David R. Stover, Daniel S. Pereira	2014	23
7	Molecular Characterization of Patient-Derived Human Pancreatic Tumor Xenograft Models for Preclinical and Translational Development of Cancer Therapeutics Neoplasia ·Mike Mattie, Ashley Christensen, Mi Sook Chang, William Yeh, Suzanne Saïd, Yuriy Shostak, Linnette Capo, Alla Verlinsky, Zili An, Ingrid B.J. Joseph, Yi Zhang, Sathish Kumar-Ganesan, Karen Morrison, David R. Stover, Pia M. Challita-Eid	2013	74
8	BHQ880, a novel anti-DKK1 neutralizing antibody, inhibits tumor-induced osteolytic bone disease Cancer Research ·Seth A. Ettenberg, Feng Cong, Janine Shulok, Stefanie Urlinger, Michael Bardroff, Olga Charlat, Yuji Mishina, Shanming Liu, Mike Daley, Sharon Li, Renee Walsh, Georges Rawadi, Philippe Clément-Lacroix, Patrick Mollat, Youzhen Wang, Yung‐Mae Yao, David R. Stover	2008	5
9	Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma European Journal Of Haematology ·Martin Kaiser, Maren Mieth, Peter Liebisch, Romy Oberländer, Jessica Rademacher, Christian Jakob, Lorenz Kleeberg, Claudia Fleissner, Edgar Braendle, Malte Peters, David R. Stover, Orhan Sezer, Ulrike Heider	2008	124
10	Antitumor efficacy of LBY135, an anti-DR5 monoclonal antibody, alone or in combination with chemotherapy in human colon tumor cell lines and xenografts Cancer Research ·Jing Li, Betty Tang, Jean Cheng, Joseph Eckman, Christine Miller, Jing Yuan, Youzhen Wang, Deborah Knee, Quinn L. Deveraux, Marc Nasoff, David R. Stover	2007	5
11	Tumor-cell specific cytotoxic activity of LBY135, a novel anti- DR5 agonistic antibody Cancer Research ·Jing Li, Qingxiu Zhang, Jennifer Johnson, Deborah Knee, Quinn L. Deveraux, Marc Nasoff, David R. Stover	2007	3
12	Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure Clinical Microbiology and Infection ·Carlos Suñé, Lyndall E. Brennan, David R. Stover, Thomas Klimkait	2004	21
13	Novel magnetic supports for small molecule affinity capture of proteins for use in proteomics Molecular Diversity ·Irving Sucholeiki, Leticia Toledo‐Sherman, Christopher M. Hosfield, Kelly Boutilier, Leroi V. DeSouza, David R. Stover	2003	9
14	Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors Structure ·Xiaotian Zhu, Joseph L. Kim, John Newcomb, Paul Rose, David R. Stover, Leticia M. Toledo, Huilin Zhao, Kurt Morgenstern	1999	205
15	Mechanisms and kinetics of procathepsin D activation European Journal of Biochemistry ·Sergio Wittlin, Johannes Rösel, Francesco Hofmann, David R. Stover	1999	43
16	One‐step purification of cathepsin D by affinity chromatography using immobilized propeptide sequences European Journal of Biochemistry ·Sergio Wittlin, Johannes Rösel, David R. Stover	1998	16
17	Modulation of the SH2 Binding Specificity and Kinase Activity of Src by Tyrosine Phosphorylation within Its SH2 Domain Journal of Biological Chemistry ·David R. Stover, Pascal Furet, Nicholas Lydon	1996	75
18	Synthesis of Potent and Orally Active HIV‐Protease Inhibitors Archiv der Pharmazie ·Hans‐Georg Capraro, Guido Bold, Alexander Fässler, Robert Cozens, Thomas Klimkait, Janis Lazdins, Jürgen Mestan, Bernard Poncioni, Johannes Rösel, David R. Stover, Marc Lang	1996	6
19	Src Phosphorylation of the Epidermal Growth Factor Receptor at Novel Sites Mediates Receptor Interaction with Src and P85α Journal of Biological Chemistry ·David R. Stover, Michael Becker, Janis Liebetanz, Nicholas Lydon	1995	188
20	Protein-Tyrosine Phosphatase Activity of CD45 Is Activated by Sequential Phosphorylation by Two Kinases Molecular and Cellular Biology ·David R. Stover, Kenneth A. Walsh	1994	7

About David R. Stover

David R. Stover is a scholar working on Hematology, Oncology, Immunology and Allergy, Virology and Genetics, having authored 47 papers that have together received 3.0k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (8 papers), HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Multiple Myeloma Research and Treatments (5 papers), Protein Kinase Regulation and GTPase Signaling (5 papers), HIV/AIDS drug development and treatment (5 papers), Cell Adhesion Molecules Research (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Hematology (960 citations), Gastroenterology (258 citations), Oncology (1.1k citations), Genetics (408 citations) and Molecular Biology (1.4k citations). David R. Stover has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Nicholas Lydon, Sayuri Ohno-Jones, Catherine L. Cioffi, Elisabeth Buchdunger, Norman M. Law, Brian Druker, Janis Liebetanz, Kenneth A. Walsh, Michael Becker and Huilin Zhao. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Molecular Cancer Therapeutics, European Journal of Biochemistry and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact